Hode T.,ImmunoPhotonics Inc. |
Jenkins P.,Irradia United States |
Jordison S.,Irradia AB |
Hode L.,Swedish Laser Medical Society
Progress in Biomedical Optics and Imaging - Proceedings of SPIE | Year: 2011
In a series of experiments we investigated the extent to which coherence is preserved in tissue. We investigated whether the decrease in coherence length is dependent upon the coherence length of the illuminating light and possibly also if the light is polarized. We compared highly coherent light from a HeNe laser, and less coherent light from a semiconductor laser, in scattering media such as raw ground beef. We studied the laser speckle contrast after passing through 1 - 2 cm of meat. The conclusion is that the laser light is still coherent enough to form laser speckles after passing through a 2 cm thickness of meat. © 2011 SPIE. Source
Jenkins P.A.,SpectraMedics Pty Ltd. |
Jenkins P.A.,SpectraVET Inc. |
Jenkins P.A.,ImmunoPhotonics Inc. |
Carroll J.D.,THOR Photomedicine Ltd.
Photomedicine and Laser Surgery | Year: 2011
Background: Dose and beam parameters are critical for successful laser, LED, and other light therapy treatments; however, in our experience, researchers frequently make critical errors and omissions when submitting papers for publication. Journals frequently publish studies with missing data, mathematical errors, and no reported verification of beam parameters. This makes reproducibility impossible, and further confounds an already complex subject. Objective: This article is intended to be a reference document for non-physicist researchers conducting low-level laser therapy (LLLT) laboratory studies and clinical trials to help them design and report the beam and dose aspects of their trials. Recommendations: It provides a checklist to help LLLT researchers understand and report all the necessary parameters for a repeatable scientific study. It includes the eight most important beam parameters to report, which are: wavelength, power, irradiation time, beam area at the skin or culture surface (this is not necessarily the same as the aperture size), pulse parameters, anatomical location, number of treatments, and interval between treatments. The three commonly used dose parameters are time, energy, and energy density. In addition, more thorough reporting would include coherence, application technique (contact, projection, scanning, pressure), beam profile, and spectral width, as these may also be considered important. Beam power often decreases as the device warms up and as the device ages; therefore, this should be checked routinely during an experiment/trial. Measurements of beam area and beam power require special instruments and trained technicians to operate them. Power measurements should be taken before, after, and at frequent intervals during research trials. Conclusion: Reviewers should insist that the minimum eight most important beam parameters are included, and authors should take care to measure and record these accurately before, during, and after an experiment or clinical trial. © Copyright 2011, Mary Ann Liebert, Inc. Source
ImmunoPhotonics Inc. | Date: 2013-01-17
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.
ImmunoPhotonics Inc. | Date: 2009-10-06
Li X.,Chinese PLA General Hospital |
Min M.,Affiliated Hospital of Academy of Military Medical science |
Du N.,Chinese PLA General Hospital |
Gu Y.,Chinese PLA General Hospital |
And 5 more authors.
Clinical and Developmental Immunology | Year: 2013
With the development of cancer immunotherapy, cancer vaccine has become a novel modality for cancer treatment, and the important role of adjuvant has been realized recently. Chitin, chitosan, and their derivatives have shown their advantages as adjuvants for cancer vaccine. In this paper, the adjuvant properties of chitin and chitosan were discussed, and some detailed information about glycated chitosan and chitosan nanoparticles was also presented to illustrate the trend for future development. © 2013 Xiaosong Li et al. Source